Table 2.
Peripheral Blood Lymphocyte Subsets Among Transplant Patients With CMV Disease, CMV Infection, and Those Who Did Not Develop CMV Infection
| CMV Disease | CMV Infection | No CMV Infection | P Value | |
|---|---|---|---|---|
| SOT (n = 36) | n = 7 | n = 18 | n = 11 | |
| Pretransplant median PBALC (IQR), /µL | 1140 (800–1790) |
1260 (855–1595) |
890 (660–1590) |
.55 |
| Median PBALC at 1st CMV (IQR), /µL | 270 (140–460) |
450 (388–675) |
1120a (590–1400) |
.001 |
| HSCT (n = 28) | n = 3 | n = 15 | n = 10 | |
| Pretransplant median PBALC (IQR), /µL | 560 (16–1060) |
970 (730–1080) |
780 (483–1355) |
.39 |
| Median PBALC at 1st CMV (IQR), /µL | 520 (300–560) |
510 (330–670) |
1020a (795–3308) |
.03 |
Abbreviations, CMV, cytomegalovirus; HSCT, hematopoietic stem cell transplantation; IQR, interquartile range; PBALC, peripheral blood absolute lymphocyte count; SOT, solid organ transplantation.
aUse PBALC on the first day of CMV virological testing.